News

Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases

Appointment of seasoned executives with substantial industry expertise strengthens team as the company advances programs into the clinicCAMBRIDGE, Mass., Dec.…

1 year ago

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart’s human "Heart-in-a-Jar" to assess cardiac pump performance…

1 year ago

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco

ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies. - Inflammasome ASC Inhibitor IC 100…

1 year ago

VITAS® Healthcare Unveils Inpatient Hospice Unit at Lee Memorial Hospital

The home-like facility in Southwest Florida is expected to serve 400+ patients each yearFORT MYERS, Fla., Dec. 18, 2024 (GLOBE…

1 year ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Key preclinical milestone for novel, non-opioid extended-release pain therapeutic   SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.…

1 year ago

Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…

1 year ago

Streamline Health® Expands Presence In Texas with 400-Bed Health System for RevID

Oracle Health partnership enables 400-bed Texas-based health system to leverage RevID’s automated charge reconciliation to improve financial performanceATLANTA, Dec. 18,…

1 year ago

Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases

Partnership leverages proprietary PHICS™ technology to bring together a kinase and target of interest to modulate protein function, in this…

1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1…

1 year ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials…

1 year ago